. Author manuscript; available in PMC: 2012 Jun 1.

Published in final edited form as: J Thorac Oncol. 2011 Jun;6(6):1059–1065. doi: 10.1097/JTO.0b013e318215a4dc

Table 3. Smoking outcomes.

	ALL (n=46)	INTERVENTON (n=32)	CONTROL (n=14)	OR (95% CI.)
7-DAY POINT PREVALENCE TOBACCO ABSTINENCE
2 weeks
Self-reported	17/46 (37.0%)	13/32 (40.6%)	4/14 (28.6%)	1.23 (.34-4.52)
⁺ Cotinine-confirmed (version 1)	16/46 (34.8%)	12/32 (37.5%)	4/14 (28.6%)	1.50 (.38-5.86)
^* Cotinine-confirmed (version 2)	11/46 (23.9%)	9/32 (28.1%)	2/14 (14.3%)	2.35 (.44-12.64)
12 weeks
Self-reported quit	17/46 (37.0%)	14/32 (43.8%)	3/14 (21.4%)	2.85 (.67-12.22)
Cotinine-confirmed (version 1)	15/46 (32.6%)	13/32 (40.6%)	2/14 (14.3%)	4.11 (.79-21.48)
^* Cotinine-confirmed (version 2)	13/46 (28.3%)	11/32 (34.4%)	2/14 (14.3%)	3.14 (.59-16.62)

⁺

Analysis with insufficient returned saliva samples counted as nonsmokers.

Analysis with insufficient returned saliva samples counted as smokers.